Clinilabs Selected for a Phase II Study of Major Depressive Disorder
Clinilabs, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced that they have been selected to conduct a Phase II clinical research study of an investigational medication in patients with Major Depressive Disorder.
The trial will examine the effects of an investigational medication in treatment resistant patients who are experiencing a current episode of depression. This is Clinilabs’ fifth study in this therapeutic area. Dr. Stephen Murray, Clinilabs’ Chief Medical Officer states: “Major Depressive Disorder is a debilitating disease that carries with it both emotional and physical symptoms. I am pleased to be involved in a clinical trial that is assessing a novel medication that may combat this condition.”
Enrollment for this study has begun. Referrals from physicians and other healthcare providers are welcomed. Individuals in the New York City Metro area who suffer from Major Depressive Disorder can contact our call center at 212-994-4567 to prequalify. Additional information may also be found by visiting www.clinilabs.com/mdd.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
